| Type | Public |
|---|---|
| Traded as | NASDAQ: AEZS TSX: AEZ |
| Industry | Biotechnology |
| Headquarters | Quebec, Canada |
| Key people | Prof. Juergen Engel, Ph.D. |
| Website | www.aezsinc.com |
Æterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) is a Quebec, Canada-based biopharmaceutical company focused in oncology and endocrine therapy. It has over 100 employees in Canada, USA and Germany. The company is based in Canada, the development and research site ist based in Germany. AEterna Zentaris recently received FDA fast track and orphan status for Perifosine, a drug with multiple niche applications in cancer treatment.[1]
References
External links
 |
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
 |
This article about a Canadian corporation or company is a stub. You can help Wikipedia by expanding it. |
 |
This Quebec-related article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
This article is licensed under the Creative Commons Attribution/Share-Alike License. It uses material from the Wikipedia article Æterna Zentaris.
